About Alpha-1-antichymotrypsin
Alpha-1-antichymotrypsin (SERPINA3) is a protein
from Homo sapiens identified by UniProt accession
P01011, 423 residues long.
MolForge cross-references it against 0 known binders and
422 disease associations.
Target properties
| Protein name | Alpha-1-antichymotrypsin |
| UniProt accession | P01011 |
| Gene | SERPINA3 |
| Organism | Homo sapiens |
| Length | 423 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (422)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.37
- cathepsin L1 measurement · score 0.26
- alpha-1-antichymotrypsin complex measurement · score 0.25
- alpha-1-antichymotrypsin measurement · score 0.25
- breast adenocarcinoma · score 0.25
- glioblastoma multiforme · score 0.16
- sex hormone-binding globulin measurement · score 0.15
- total blood protein measurement · score 0.13
- peripheral arterial occlusive disease 1 · score 0.12
- serum albumin measurement · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P01011-F1 | alphafold | PREDICTED | 85.21 | — |
Amino-acid sequence (423 residues)
MERMLPLLAL GLLAAGFCPA VLCHPNSPLD EENLTQENQD RGTHVDLGLA SANVDFAFSL YKQLVLKAPD KNVIFSPLSI STALAFLSLG AHNTTLTEIL KGLKFNLTET SEAEIHQSFQ HLLRTLNQSS DELQLSMGNA MFVKEQLSLL DRFTEDAKRL YGSEAFATDF QDSAAAKKLI NDYVKNGTRG KITDLIKDLD SQTMMVLVNY IFFKAKWEMP FDPQDTHQSR FYLSKKKWVM VPMMSLHHLT IPYFRDEELS CTVVELKYTG NASALFILPD QDKMEEVEAM LLPETLKRWR DSLEFREIGE LYLPKFSISR DYNLNDILLQ LGIEEAFTSK ADLSGITGAR NLAVSQVVHK AVLDVFEEGT EASAATAVKI TLLSALVETR TIVRFNRPFL MIIVPTDTQN IFFMSKVTNP KQA
Explore Alpha-1-antichymotrypsin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets